Your web browser is out of date.

For your security and improved experience online, please update your browser.

This site is intended for healthcare professionals only
×
Share this article
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email
Share on print
Print

Digest: Amnion grafts for diabetic foot ulcers — yes or no?

Welcome to the latest Diabetes Digest which, as ever, includes my commentary and some other publications that you might find interesting and useful in your daily practice. The paper that I have chosen to comment upon is a systematic review by Lakmal et al (2021) on the rationale for the use of amniotic membrane allografts in the treatment of diabetic foot ulcers (DFUs). The push to use amniotic membranes in the treatment of DFUs has been slow, but will surely become more prominent when considering claims of improved healing rates of hard-to-treat DFUs. This systematic review, as well as others in the literature, seeks to address the effectiveness of the use of these membranes. The authors used a standard methodology searching Pubmed, Cochrane library and Google scholar from January 1, 2000, and March 30, 2020, using the search terms “Amnion” OR “Placenta” AND “Diabetic foot” (MeSH terms) in the title or the abstract field. The authors searched for observational studies in terms of randomised controlled trials, prospective cohort studies, retrospective cohort studies and case series. In all, 64 citations were identified and all were from 2010 onwards.

Eligibility criteria included: full text papers, presence of diabetes type 1 and 2, and different preparation of amniotic allografts (dehydrated, cryopreserved and stem cell extractions). RCTs comparing amniotic membrane versus standard or conventional care were included. Studies designed with the aim of analysing the molecular basis without measuring clinical improvement of the ulcers were excluded, as were case studies. Data were extracted on trial design, study setting, amniotic membrane preparation methods used, control interventions, outcome measures and statistical analysis. Outcome measure data regarding healing time, percentage healed, recurrences and adverse outcomes were extracted.

From 64 identified studies, only 12 met the inclusion criteria. Of these, eight were RCTs (5 multicentre) involving 454 patients (244 amnion, 210 control) with a mean ulcer size 5 cm2, two were prospective studies (28 amnion treated) and two were retrospective studies (92 amnion treated) with a mean ulcer size ≥5 cm2. All these studies except one (from Spain) were conducted in the USA. The DFU locations were varied with a mean duration of >28 days. The mean healing times for the amnion groups was very varied but significantly faster ranging from 3 to 26 weeks compared with the control groups.

In six RCTs, the follow-up duration was 12 weeks, while in the other two, it was 6 weeks. The prospective and retrospective studies included data until complete wound closure was achieved.

Just two of the studies examined ulcer recurrence rates, with one showing a recurrence rate in the amnion group of 14.3% versus 83.3% at 90 days, while the other found 5% recurrence versus 14% in the amnion and control group, respectively, at 112 days.

The different amniotic products used were Amnioband® (MTF Biologics), AmnioExcel® (Integra), EpiFix (MiMedx), Apligraf® (Organogenesis), Grafix® (Osiris), NEOX® CORD (Amniox Medical). The authors conclude that the current evidence suggests the use of amniotic membrane preparations for resistant DFUs may achieve relatively fast healing wound rates, but more evidence is required. In summary, I believe further research is needed, particularly in regards to ulcer relapse.

Lakmal K, Basnayake O, Hettiarachchi (2021) Systematic

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.